Back to Top Skip to main content Skip to sub-navigation

WRNMMC’s participation in APOLLO program furthers cancer research

Two groups of vials on a table Vials containing DNA samples from studies of the genetic risk for cancer at the Cancer Genomics Research Laboratory, part of the National Cancer Institute's Division of Cancer Epidemiology and Genetics. (Photo by Daniel Sone, National Cancer Institute.)

Recommended Content:

Research and Innovation | Health Readiness

As cancer survivors, oncologist, researchers, providers and family members celebrated World Cancer Day today, the researchers, providers and support staff at the John P. Murtha Cancer Center (MCC) at Walter Reed National Military Medical Center in Bethesda, Maryland remain focused on the studying not only the effects of the deadly disease, but also best possible treatment options.

The MCC serves as the preeminent cancer research and treatment facility within the Department of Defense, and has been since the 1990s. In 2012, the center was renamed after Congressman John P. Murtha, a 30 year Marine Corps veteran and long-time advocate for cancer research within the Department of Defense.

The current Director of MCC and its Research Program, Dr. Craig Shriver, is focused on the threat cancer poses on the readiness of the United States Armed Forces. According to Shriver, there are more than 1,000 active duty service members diagnoses with cancer each year, and there are more than 8,000 active duty service members living with a cancer diagnosis. Researchers at the MCC are keenly interested in how cancer affects younger people, since most active duty service members are under the age of 35, Shriver explained.

To combat the effect cancer has on the readiness of the DOD’s mission, MCC has done research into the genetic causes of cancer. According to Shriver, MCC centers have been sequencing the genome of tumors for different cancer since the 1990s. According to Shriver, since the DoD has a disproportionately high number of African American’s compared to the general U.S. population, sequencing of tumors from African Americans with prostate cancer has shown certain genetic risk factors that had not been found previously. “This is research that not only benefits African American service members, but people of African descent worldwide,” says Shriver.

Currently the MCC is using genetic sequencing as part of its participation in the APOLLO (Applied Proeogenomics Organizational Learning Outcomes) research program. According to the National Cancer Institutes’ webpage, APOLLO is part of the Cancer Moonshot initiative, a tri-federal research program that began in 2016 under the leadership of then Vice President Joe Biden. APOLLO brings together the DOD through MCC, the departments of Veterans Affairs; and the department of Health and Human Services through the NCI. According to Shriver the three agencies work together in sharing research and information, as well as publishing the results of the program.

A group of medical researchers in a line, sitting down in front of monitors
Researchers at the John P. Murtha Cancer Center at WRNMMC study the genetic makeup of cancer cells. As part of the APOLLO research program, the Murtha Cancer Center is undergoing studies related to the genetics found in the tumors of cancer patients. The genetic sequencing of these tumors is leading to new discoveries in the treatment of cancer within active duty service members in the DOD. (Photo courtesy of Walter Reed National Military Medical Center.)

APOLLO studies the genetic components of tumors from cancer patients. According to Shriver, every newly diagnoses cancer patient in on of the Murtha facilities are given the option to join the research program. If a patient opts in, their tumor is run through all available molecular platforms looking at its DNA, RNA, and Protein structure.

According to NCI, the data from the APOLLO program will be “curated and made available publicly through the Genomic Data CommonsProteomic Data Portal, and Cancer Imaging Archive.  Using all of the data available (analytical, invasive, noninvasive, and clinical) will enable researchers to study the relationships among these data, validate results, and develop predictive and prognostic models to improve patient care.”

According to Shriver APOLLO uses precision oncology where researchers look to see if there are any special molecular signatures of an individual’s cancer that be targeted with available drugs. Shriver says that tumors of the same cancer type can have different genetic attributes, which might require different treatments. “We don’t treat every patient with colon cancer the same. You identify any unique aspects of the tumor and say, ‘okay this tumor is special in this way, we identified it through the molecular signature found in the APOLLO program’, and we treat it that way,” said Shriver.

After sequencing the genetic makeup of their tumor, a patient’s blood is then sequenced to find the DNA unique to that person. According to Shriver, many young people with cancer have a genetic germline mutation that could cause cancer. And there are 50 different genes that can lead, in isolation or combined, to an increased risk of cancers.

The APOLLO program also shares any information from their research back with the patient. “We have a very unique, almost unprecedented, genetic return of results program,” Shriver said adding “If we identify that service member X has a germline genetic mutation that could affect them, and their children, for increased cancer risk, we tell the patient that. This is unusual for a research program.”

Shriver says that this information sharing is called translational research. The gap between clinical care and research is translated and provides real benefits to patients and their providers through the genome sequencing of the patient’s blood.

The research from the APOLLO program is already starting to have real benefits to not only the DOD, but the United States population at large. According to Shriver, researchers in the program identified a new genetic signature that can distinguish between patients with lung cancer who will do well with a specific treatment from those who may not do well with said treatment. “If 20% of the population don’t do well for conventional treatment, and by sequencing the genetic of the tumor, we can find those patients and move forward with more unique options,” said Shriver.

The signature is intellectual property, and as such a patent is being filed so that it can be commercialized, and a test can go to the market. Lung cancer patients can take the panel test and providers can predict if they will do well with treatment or should try something else.

While the APOLLO program is beneficial for a more hidden side of the causes of cancer, Shriver still encourages known preventative measure should be taken by all active duty service members. Shriver says that avoiding or quitting use of tobacco and nicotine products are a good common knowledge practice.

According to Director of Gynecologic Oncology at WRNMMC, Air Force Col. (Dr.) Yovanni Casablanca, all service members regardless of gender should get the human papilloma virus, or HPV, vaccine which protects against cervical cancer.

Shriver believes genetic sequencing can be helpful to the DOD’s mission in the future outside of cancer research. According to Shriver, genetic sequencing could be utilized at military intake alongside other medical tests, to determine an individual’s genetic risk to certain cancers. “This wouldn’t be us turning someone away based on their sequencing. Instead we can use this information to help a service member who may be higher risk be aware and take proactive steps to mitigate the potential onset of certain cancers,” said Shriver.

For more information about the Murtha Cancer Center, or the APOLLO program, check their websites.

You also may be interested in...

DHA-PI 3200.01: Research and Development (R&D) Enterprise Activity (EA)

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (p): a. Establishes the Defense Health Agency’s (DHA) procedures for the Deputy Assistant Director (DAD), R&D to manage and execute, on behalf of the Assistant Secretary of Defense for Health Affairs (ASD(HA)), the portion of the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation assigned to it (referred to as the “DHP Science and Technology (S&T) Program)”. The DHP S&T Program includes Budget Activities (BAs) 6.1-6.3 and 6.6. The ASD(HA) provides policy, direction, and guidance to inform planning, programming, budgeting, and execution of the DHP RDT&E appropriation in accordance with statute, regulation, and policy in Reference (a). The DAD-R&D, and Component Acquisition Executive (CAE) manage and execute DHP RDT&E Program funds aligned to them on behalf of the ASD(HA). The CAE is responsible for managing BAs 6.4, 6.5, and 6.7 funding, as well as Procurement and Operations and Maintenance funding required to support DHP-funded Acquisition Programs, regardless of acquisition activity. b. Supports the Director, DHA, in developing appropriate DHA management models to maximize efficiencies in the management and execution of DHP RDT&E-funded activities carried out by the Combatant Commands (CCMDs), Services, Uniformed Services University of the Health Sciences (USU), Defense Agencies, and other DoD Components, as applicable. c. Codifies processes to confirm DHP RDT&E funds are applied towards medical priorities and aligned to ASD(HA) policy, direction, and guidance to develop and deliver innovative medical products and solutions that increase the readiness of the DoD medical mission in accordance with Reference (a). d. Supports the following objectives of the R&D EA: (1) Increasing the quantity, quality, and pace of medical research through improved programmatic organization, processes, and oversight. (2) Ensuring DHP RDT&E funded efforts align to ASD(HA) published program guidance that provides resourcing guidance and translates national, departmental, and Service priorities into specific program objectives. (3) Verifying alignment of DHP RDT&E funds to medical priorities and to ASD(HA) policy, direction, and guidance to ensure the development and delivery of medical materiel and knowledge solutions. (4) Facilitating coordination with the CCMDs, Services, USU, Defense Agencies, and other DoD Components, as applicable, to ensure DHP RDT&E funded activities address joint medical capability gaps, and avoid unnecessary duplication.

DHA IPM 19-003: Reserve Health Readiness Program

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (i): • Provides utilization guidance and funding requirements for the RHRP contract to supplement Reserve Component Individual Medical Readiness (IMR) and Deployment Health activities when Service organic health readiness resources are not available to meet mission requirements. • Provides utilization guidance and funding requirements for the RHRP contract for Active Duty enrolled in TRICARE Prime Remote, U.S. Coast Guard (USCG), USCG Reserves, and re-deploying DoD civilians (e.g., U.S. Army Corps of Engineers and U.S. Army Intelligence and Security Command). • Communicate procedure guidance to all DoD organizations utilizing RHRP services. • Will expire effective 12 months from the date of issue and be converted to a DHA-Procedural Instruction.

  • Identification #: 19-003
  • Date: 3/8/2019
  • Type: DHA Interim Procedures Memorandum
  • Topics: Health Readiness

DHA PI 6025.07: Naloxone in the MTFs

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (h), establishes the Defense Health Agency’s (DHA) procedures for prescribing and dispensing naloxone by pharmacists in MTFs to eligible beneficiaries, upon beneficiary request, or when the pharmacist determines the beneficiary meets the established criteria for being at risk for a life-threatening opiate overdose.

DHA PI 6200.05: Force Health Protection Quality Assurance (FHPQA) Program

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (ab), establishes the procedures for the FHPQA Program as defined in Reference (z). This DHA-PI applies to: a. OSD, the Military Departments (including the United States Coast Guard (USCG) at all times, including when it is a Service in the Department of Homeland Security by agreement with that Department), the Office of the Chairman of the Joint Chiefs of Staff (CJCS) and the Joint Staff, the Combatant Commands, the Office of the Inspector General of the DoD, the Defense Agencies, the DoD Field Activities, and all other organizational entities within the DoD (referred to collectively in this DHA-PI as the “DoD Components”). b. Civilian personnel, as defined in Reference (e), and DoD contractor personnel authorized to accompany the force (CAAF), in accordance with References (j), (m), and (n), respectively.

  • Identification #: DHA PI 6200.05
  • Date: 5/2/2018
  • Type: DHA Procedural Instruction
  • Topics: Health Readiness

DoD Instruction 6200.05: Force Health Protection Quality Assurance (FHPQA) Program

Policy

This issuance establishes policy, assigns responsibilities, and defines requirements for the development and establishment of the FHPQA Program in accordance with the authority in DoD Directive (DoDD) 5124.02, Sections 731 and 738 of Public Law 108-375; Sections 1074f, 1092a, and 1073b of Title 10, United States Code; and DoDDs 6200.04 and 5136.13.

DoD Instruction 6490.13: Comprehensive Policy on Traumatic Brain Injury-Related Neurocognitive Assessments by the Military Services

Policy

This instruction establishes policy, assigns responsibilities, and prescribes standard elements, pursuant to section 722 of Public Law 111-383, requiring the implementation of a comprehensive neurocognitive assessment policy in the Military Services.

Embedded Fragment Analyses

Policy

Clarification of the Requirement for Continuation of Semi-Annual Reporting of Results of Embedded Fragment Analyses

Detecting and Reporting DoD Cases of Ebola Virus Disease Infection

Policy

Guidance as of 17 OCT 2014 from the Department of Defese (AFHSC)for Detecting and Reporting DoD Cases of Ebola Virus Disease Infection

Influenza Surveillance Program

Policy

Sentinel Sites for the 2014-2015 Influenza Surveillance Program

Deployment Limiting Mental Disorders and Psychotrophic Medications

Policy

Policy memorandum about Deployment Limiting Mental Disorders and Psychotrophic Medications

DoD Laboratories Participating in CDC Laboratory Response Network 03-213

Policy

Department of Defense (DoD) laboratories participating in the Centers for Disease Control and Prevention-sponsored Laboratory Response Network (LRN) do so with the approval and support of their respective Military Department Surgeons General.

  • Identification #: 03-213
  • Date: 3/26/2013
  • Type: Memorandums
  • Topics: Health Readiness

Medical Planning and Programming Lexicon

Policy

DoD Instruction Number 6490.11: DoD Policy Guidance for Management of Mild Traumatic Brain Injury/Concussion in the Deployed Setting

Policy

This instruction establishes policy, assigns responsibilities, and provides procedures on the management of mild traumatic brain injury (mTBI), also known as concussion, in the deployed setting.

Guidance on the Establishment of a Human Cell, Tissue, and Cellular and Tissue Based Products Program

Policy

This memorandum requests the Services resource a Human Cell, Tissue, and Cellular and Tissue Based Products (HCT/Ps) Program that complies with regulatory standards for management and oversight of HCT/Ps, according to the best fit for their Service.

Access to Medical Services Who were Exposed to Rabies in Combat Theater

Policy
<< < 1 2 > >> 
Showing results 1 - 15 Page 1 of 2

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.